CN102000299B - 一种治疗高脂血症的药物 - Google Patents
一种治疗高脂血症的药物 Download PDFInfo
- Publication number
- CN102000299B CN102000299B CN2010105362091A CN201010536209A CN102000299B CN 102000299 B CN102000299 B CN 102000299B CN 2010105362091 A CN2010105362091 A CN 2010105362091A CN 201010536209 A CN201010536209 A CN 201010536209A CN 102000299 B CN102000299 B CN 102000299B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- blood
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 12
- 241000195474 Sargassum Species 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 241000218628 Ginkgo Species 0.000 claims description 10
- 235000011201 Ginkgo Nutrition 0.000 claims description 10
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 10
- 238000012856 packing Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 235000005903 Dioscorea Nutrition 0.000 claims description 7
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 7
- 241000219295 Portulaca Species 0.000 claims description 7
- 241000219780 Pueraria Species 0.000 claims description 7
- 241001165494 Rhodiola Species 0.000 claims description 7
- 235000004879 dioscorea Nutrition 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 238000003672 processing method Methods 0.000 claims description 3
- 244000281702 Dioscorea villosa Species 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 28
- 210000003734 kidney Anatomy 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 18
- 230000007812 deficiency Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241001474374 Blennius Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 74
- 239000008280 blood Substances 0.000 description 74
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 31
- 210000004185 liver Anatomy 0.000 description 24
- 230000001737 promoting effect Effects 0.000 description 16
- 235000009508 confectionery Nutrition 0.000 description 15
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 239000003172 expectorant agent Substances 0.000 description 13
- 230000003419 expectorant effect Effects 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 12
- 230000001603 reducing effect Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 7
- 241000234273 Dioscorea Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- -1 anthraquinone compounds Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000000489 anti-atherogenic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 235000014659 low sodium diet Nutrition 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗高脂血症的药物,主要采用红景天、女贞子、决明子、姜黄、绞股蓝、海藻、制首乌、泽泻等中药材作为药物的主剂,制作方法简单、成本低廉,采用沏服的方法,方便了病人的携带和服用,同时对于治疗高脂血症特别是中医辨证属脾肾两虚者有着较好疗效,适合各个年龄段的患者使用。
Description
技术领域
本发明涉及一种药品,具体涉及一种治疗高脂血症的药物。
背景技术
近年来,随着人们饮食结构及生活方式的变化,越来越多的人血脂水平呈逐年升高趋势。高脂血症是指由于脂肪代谢或运转异常使血浆中一种或几种脂质高于正常值,是心脑血管性疾病及糖尿病的危险因素,因此有效地控制高脂血症是预防心脑血管疾病的重要方法。
高脂血症的基本病因病机是由于患者生活习惯不良,长期过食肥甘厚味.加之活动减少,脏腑气机不利,功能失调,污秽浊脂留于血脉之中致使津液凝滞。中老年人由于肾气亏虚,脾肾功能失调,运化失常,气化失司,导致血流速度减慢,加之膏脂输化不利,血脂浓度升高,污秽浊脂沉积于血管,阻碍血流正常运行,最终导致瘀血形成,故痰浊、瘀血是中老年血脂代谢紊乱的主要确切病理因素,痰浊、瘀血阻滞经脉是高脂血症的重要的病理基础。由此可见,中医治疗高脂血症的关键是痰瘀并重,痰瘀同治。痰之与瘀,同源异物,相互依赖,交融缠结.难消难化。治疗单去痰则瘀难消,仅逐瘀则痰难化,只有两者兼顾,祛痰以助化瘀,化瘀以利祛痰,如此痰瘀同治,才能切中病机。治宜活血化瘀、通经疏络、健脾化湿、祛痰泄浊、益肾养肝共达祛除污秽浊脂,降低血脂功效。
目前,临床上多采用西药治疗,但由于西药的毒副作用较大,可造成肝肾直接损害,部分患者不能耐受,且部分血脂控制不良,总体治疗效果不能令人满意;目前市场上还有一些治疗高脂血症的中药,有些属于治标不治本,有些使用价格昂贵的成分;有些在应用过程中由于疗效不确切而中断使用;还有一些的使用方法较为繁琐不适宜大范围使用。
发明内容
为解决上述治疗高脂血症的各种难题,本发明提供了一种新的治疗高脂血症的药物,采用红景天、女贞子、决明子、姜黄、海藻、制首乌、泽泻等中药材制成药袋,采用沏服的方法代茶饮用,本发明从高脂血症的发病根源入手,从根本上有效的治疗高脂血症,疗效显著,使用方便,价格低廉且没有毒副作用。
按中医理论,高脂血症主要是饮食不节,过食肥甘,损伤脾胃,同时肝胆 疏泄功能不畅,不能泌输精汁而引起脾之消谷运行功能失调,或有肾气亏虚,脾肾功能失调,运化失常,气化失司,转化为痰浊。由于痰浊滋生,浸淫脉管,脂质浆积,血行受阻,经脉痹阻,是故肾精不足,气滞湿阻、痰凝血瘀具见而发病。
依据以上发病机理及其治疗原则,同时根据发明人多年的临床经验,该治疗高脂血症的药物的各组份,按照重量份计,其配比为:荷叶2.5-3.5份,山药3-6份,麦芽3-5份,大黄1-2份,姜黄2-3.5份,泽泻3-4份,女贞子2-3.5份,葛根2-4份,制首乌2.5-3.5份,决明子5-7份,海藻2-4份,甘草0.5-1份,茯苓3-5份,红景天3-5份,马齿苋3-5份,绞股蓝3-5份,山楂5-7份,丹参3-6份,银杏叶1-2份。
经过发明人的长期研究和试制,最终发现了上述中药的配比为下述值时,治疗的效果最好。该配比的重量份为:荷叶3份,山药5份,麦芽4份,大黄1.5份,姜黄3份,泽泻3份,女贞子3份,葛根3份,制首乌3份,决明子6份,海藻3份,甘草1份,茯苓4份,红景天3份,马齿苋4份,绞股蓝4份,山楂6份,丹参4份,银杏叶1.5份。
方中荷叶味苦涩,性平,归肝、脾、胃、心经,有清暑利湿、升发清阳、凉血止血、降血脂等功效。茯苓味甘、淡,性平,归心、肺、脾、肾经,可利水渗湿、宁心安神、健脾和胃,其淡能利窍,甘以助阳,为除湿之圣药,味甘平补阳,益脾逐水,治水缓脾,生津导气。姜黄味辛、苦,性温,归肝、脾经,可破血行气、通络止痛、兼理气血,其苦益火生气,辛温达火化气,气生化则津液行于三阴三阳,清者注于肺,浊者注于经,溜于海,而血自行,是理气散结而泄血也,有明显降血脂作用。丹参味苦,性微寒,归心、肝、心包经,可活血祛瘀、养血安神、通调经脉、生新血、去恶血、善治血分、善疗风而散结,性平和而走血,血行则积自行,为调理血分首药,能明显降低血清总胆固醇、甘油三酯、低密度脂蛋白,减轻血管内皮损伤,具有抗动脉粥样硬化作用,能扩张周围血管,降低血压,促进脂肪在肝脏内氧化加强,素有“一味丹参,功同四物”之称。
制首乌味苦、甘、涩,性微温,归肝、肾经,可补精养血、滋阴熄风,其味甘涩,性微温而不燥,能养血滋阴、补养肝肾、收敛精气、为平补阴血之良药,凡血虚衰弱、头晕眼花、腰膝酸软、年老体弱精亏、肠燥便秘,皆可应用,其补肾之力似地黄而不腻膈,补肝之力似白芍而不破泄,为补虚益精之良药, 具显著的调血脂、防治动脉粥样硬化作用。制首乌在体外能与胆固醇相结合,可减少胆固醇的吸收;其所含蒽醌化合物还能促进肠蠕动,抑制胆固醇在肠道再吸收,并促进胆固醇代谢。山药味甘,性平,归肝、脾、肺经,可补脾、养肺、固肾、益精,使中土调和、肌肉充足、补中而益气力。麦芽味甘,性平,归脾、胃经,可消食化积,有降血脂和护肝作用。大黄味苦,性寒,归脾、胃、肝、大肠经,可攻积滞、清湿热、泻火祛瘀、破积聚、留饮宿食、荡涤肠胃、推陈致新、通利水谷、调中化食、安和五脏、通宣气机、调血脉、利关节、泄壅滞水气,其味苦气香性凉,能入血分破一切瘀血,兼入气分,亦能调气,能显著降低血清总胆固醇。
《神农本草经》将泽泻列为上品,谓“久服轻身面生光”。其味甘淡,性寒,归肾、膀胱经,可利水渗湿、泄热通淋、益气力、养五脏、补虚损五劳、除五脏痞满、祛血中之痰浊,具有降低血清胆固醇、甘油三酯的作用,并能干扰胆固醇的吸收、分解、排泄,控制外源性胆固醇和甘油三酯的吸收,影响内源性胆固醇的代谢,加速甘油三酯的分解或影响肝脏对其合成,阻止脂类在血清内滞留,促进血浆中的TC的运输和清除,有降血脂和抗动脉粥样硬化作用。女贞子味甘、苦,性凉,归肝、肾经,可补益肝肾、清虚热、明目、通络和血、补中、安五脏、养精神、除百疾,有降血脂预防动脉硬化作用。葛根味甘、辛,性平,归脾、胃经,可解肌发表、生津升阳、降低血清胆固醇。海藻味成,性寒,归肝、肾、胃经,可消痰软坚、利水退肿,其主通经脉,使人身十二经脉流通,主治经脉内外之坚结,可显著降低血清总胆固醇含量,增加高密度脂蛋白含量,减少动脉内膜病变和粥样斑块的形成。
决明子味苦、甘、成,性微寒,归肝、肾、大肠经,成得水气,甘得土气,能补血,苦可泄热,平和胃气,寒能益阴,可清肝益肾,明目利水,祖国医学还认为“凡子皆降”,故其既具有调脂作用又有降压作用;所含槲皮素等酮类化合物能抑制肠道对外源性胆固醇的吸收;所含大黄素等蒽醌类化合物能增加肠道蠕动,促进排便,从而使血清胆固醇下降,并能抑制动脉粥样硬化斑块的形成。红景天味甘、涩,性寒,归肺、脾经,补气清肺、健脾益气、活血化瘀、益智养心、收涩止血。马齿苋味酸,性寒,归肝、大肠经,清热解毒、凉血除湿、性寒滑利、善入血分,有降胆固醇作用。绞股蓝味甘、苦,性微寒,归肺脾肾经,能益气、安神、降血脂、清热解毒、止咳祛痰。
山楂味酸、甘,性微温,归脾、胃、肝经,可消食积、化瘀滞、善入血分而化瘀血不伤新血,兼入气分而开气郁痰结不伤正气,可显著降低血清总胆固醇及低密度脂蛋白含量,增加高密度脂蛋白含量,减少胆固醇在动脉壁中的沉积,所含黄酮类化合物对肾上腺索引起的微循环障碍有促进微动脉血流恢复及管径恢复作用,对心肌细胞缺氧性损伤有明显保护作用,对心脏血流动力学及心肌氧代谢有一定调整作用;小剂量山楂能抑制血小板聚集,大剂量山楂对血小板聚集有促进解聚作用,是治疗高脂血症的常用良药。银杏叶味苦、甘、涩,性平,小毒,归心、脾、肺经,可活血养心、敛肺涩肠,治疗高总胆固醇血症。甘草补脾益气、清热化痰、调和诸药。全方共奏活血化瘀、通经疏络、健脾化湿、祛痰泄浊、益肾养肝之功,以达祛除污秽浊脂、降低血脂之效。
方中山楂、麦芽合用可降脂护肝;麦芽、茯苓合用可健脾化痰祛湿;山楂、荷叶合用可活血散瘀;红景天、山药、葛根、茯苓、泽泻合用可健脾利湿,除痰降脂;丹参、山楂合用活血化瘀,既能逐瘀破血、通经活络,又破瘀血而不伤新血;制首乌与女贞子共同补益肝肾,通络和血。
方中尤以山楂、决明手、海藻、绞股蓝、制首乌、泽泻、荷叶、姜黄为主药,诸药合用具有活血化瘀、固精益肾、利湿化痰、降浊功效。本法之关键在于痰瘀并治,祛痰除湿以畅通经络、清利积湿;活血化瘀以剔除瘀淤、健运血循,如此机体瘀化痰清,自能体健无虞。
本发明的加工方法为:将以上各组份原料药物混合均匀,置入中药粉碎机中共同粉碎成粗末,粗末可过50-100目筛即可,如果粉碎的过细,会造成药物在沸水沏制的过程中很快流失,影响药效,不利于药物的重复冲泡。将粉碎后的粗药末装入滤纸袋,每36克混合药末为一袋包装为成品,此剂量既能达到较好的治疗效果又使沏服的口感不过苦涩。
患者采用沸水沏服,每次服用一袋,每日服两次。服用30天为一疗程。一般服用3个疗程即可有显著效果。
本发明所提供的治疗高脂血症的药物,从发病根源入手,从根本上有效的治疗高血脂症;由于采用的均为中国的传统中药,价格低廉可以大范围的推广使用,同时由于采用了冲泡的方法,可以代替茶饮,更有利于患者的服用,适合各种年龄段的患者服用;疗程时间短,见效快,经过临床实验大多数患者服用3个疗程后,总有效率在90%以上;由于均采用纯天然的中药材,减少了药物的毒副作用;采用过滤袋的包装,既方便了日常的饮用,又方便携带可以随时用药。
具体实施方式
实施例1
一种治疗高脂血症的药物,各组份按照重量份计,其配比为:荷叶3份,山药3份,麦芽5份,大黄1.2份,姜黄3.5份,泽泻3份,女贞子3.2份,葛根2份,制首乌2.7份,决明子6份,海藻2.5份,甘草1份,茯苓4.5份,红景天5份,马齿苋3份,绞股蓝3.5份,山楂7份,丹参5份,银杏叶1.5份。
加工时将以上各组份原料药物按配比混合均匀,置入中药粉碎机中共同粉碎成粗末,粗末可过100目筛即可,将粉碎后的粗药末装入滤纸袋,每36克混合药末为一袋包装为成品。
实施例2
一种治疗高脂血症的药物,各组份按照重量份计,其配比为:荷叶2.5份,山药5份,麦芽3份,大黄1份,姜黄3份,泽泻4份,女贞子2份,葛根3份,制首乌3份,决明子5份,海藻4份,甘草0.5份,茯苓5份,红景天4.5份,马齿苋5份,绞股蓝4.5份,山楂6.5份,丹参4.5份,银杏叶1份。
将以上各组份原料药物混合均匀,置入中药粉碎机中共同粉碎成粗末,粗末可过80目筛即可,将粉碎后的粗药末装入滤纸袋,每36克混合药末为一袋包装为成品。
实施例3
一种治疗高脂血症的药物,各组份按照重量份计,其配比为:荷叶3.5份,山药6份,麦芽4份,大黄2份,姜黄2.5份,泽泻3.2份,女贞子3份,葛根4份,制首乌2.5份,决明子7份,海藻2份,甘草0.8份,茯苓3份,红景天3.5份,马齿苋4.5份,绞股蓝5份,山楂5.5份,丹参3份,银杏叶1.2份。
将以上各组份原料药物混合均匀,置入中药粉碎机中共同粉碎成粗末,粗末可过50目筛即可,将粉碎后的粗药末装入滤纸袋,每36克混合药末为一袋包装为成品。
实施例4
一种治疗高脂血症的药物,各组份按照重量份计,其配比为:荷叶2.7份,山药4.5份,麦芽3.5份,大黄1.8份,姜黄2份,泽泻3.8份,女贞子2.5份,葛根2.5份,制首乌3.2份,决明子6.5份,海藻3份,甘草0.6份,茯苓3.5份,红景天4份,马齿苋3.5份,绞股蓝4份,山楂5份,丹参6份,银杏叶 1.7份。
将以上各组份原料药物混合均匀,置入中药粉碎机中共同粉碎成粗末,粗末可过70目筛即可,将粉碎后的粗药末装入滤纸袋,每36克混合药末为一袋包装为成品。
实施例5
一种治疗高脂血症的药物,各组份按照重量份计,其配比为:荷叶3.2份,山药4份,麦芽4.5份,大黄1.5份,姜黄2.2份,泽泻3.5份,女贞子3.5份,葛根3.5份,制首乌3.5份,决明子5.5份,海藻3.5份,甘草0.7份,茯苓4份,红景天3份,马齿苋4份,绞股蓝3份,山楂6份,丹参4份,银杏叶2份。
加工时将以上各组份原料药物按配比混合均匀,置入中药粉碎机中共同粉碎成粗末,粗末可过60目筛即可,将粉碎后的粗药末装入滤纸袋,每36克混合药末为一袋包装为成品。
实验例1
患者柳某,男,44岁,高脂血症3年,经发明人提供,服用按照本发明实施例1所述配比和方法制得的治疗高脂血症的药物,并按照每天两次,一次一袋的剂量服用,连续服用三疗程后治愈,并嘱患者低脂低盐饮食,坚持体育锻炼,至今未复发,患者反应良好,无副作用。
实验例2
患者陈某,女,57岁,高血压病史7年,高脂血症3年,发病后每日服用西药降脂药后出现肝功异常副作用;经发明人建议,服用按照本发明实施例3所述配比和方法制得的治疗高脂血症的药物,并按照每天两次,一次一袋的剂量服用,连续服用两个疗程后显效;又服用按照本发明实施例2所述配比和方法制得的治疗高脂血症的药物,连续服用四个疗程,达到临床控制,并嘱患者低脂低盐饮食,坚持体育锻炼,患者反应良好,无副作用。
采用以上方法,共治疗患者64例,其中男36例,女28例;年龄45-75岁,平均61.2岁;病程1--16年,临床控制23例(36%),显效20例(31%),有效15例(24%),无效6例(9%),总有效率91%。对于改善眩晕、健忘、焦虑、口干、耳鸣、乏力等症状临床综合疗效,显效44例(69%),有效16例(25%),无效4例(6%),总有效率94%。
Claims (4)
1.一种治疗高脂血症的药物,其特征在于:该药物的各组份按照重量份计,其配比为:荷叶2.5-3.5份,山药3-6份,麦芽3-5份,大黄1-2份,姜黄2-3.5份,泽泻3-4份,女贞子2-3.5份,葛根2-4份,制首乌2.5-3.5份,决明子5-7份,海藻2-4份,甘草0.5-1份,茯苓3-5份,红景天3-5份,马齿苋3-5份,绞股蓝3-5份,山楂5-7份,丹参3-6份,银杏叶1-2份;
其加工方法如下:将各组份原料药物按照上述比例混合均匀,置入粉碎机中共同粉碎成粗末,将粉碎后的粗药末过50-100目筛后装入滤纸袋,包装为成品。
2.根据权利要求1所述的治疗高脂血症的药物,其特征在于:该药物的各组份按照重量份计,其配比为:荷叶3份,山药5份,麦芽4份,大黄1.5份,姜黄3份,泽泻3份,女贞子3份,葛根3份,制首乌3份,决明子6份,海藻3份,甘草1份,茯苓4份,红景天3份,马齿苋4份,绞股蓝4份,山楂6份,丹参4份,银杏叶1.5份。
3.加工权利要求1所述治疗高脂血症的药物的方法,其特征在于:该方法为:将各组份原料药物按照组方比例混合均匀,置入粉碎机中共同粉碎成粗末,将粉碎后的粗药末过50-100目筛后装入滤纸袋,包装为成品。
4.根据权利要求3所述的治疗高脂血症的药物的加工方法,其特征是:过筛后的粗末每36克混合药末为一袋,包装为成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105362091A CN102000299B (zh) | 2010-11-09 | 2010-11-09 | 一种治疗高脂血症的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105362091A CN102000299B (zh) | 2010-11-09 | 2010-11-09 | 一种治疗高脂血症的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102000299A CN102000299A (zh) | 2011-04-06 |
CN102000299B true CN102000299B (zh) | 2012-05-23 |
Family
ID=43808169
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105362091A Expired - Fee Related CN102000299B (zh) | 2010-11-09 | 2010-11-09 | 一种治疗高脂血症的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102000299B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552416B (zh) * | 2012-02-15 | 2013-12-25 | 张彬 | 一种治疗代谢综合征及习惯性便秘的中药冲剂 |
CN103285209B (zh) * | 2012-02-24 | 2014-11-26 | 烟台开发区迈得康生物技术有限公司 | 一种促进和改善微循环的保健品及其制备方法 |
CN102579712A (zh) * | 2012-03-20 | 2012-07-18 | 河南九势制药股份有限公司 | 一种降脂作用的药物制剂及其制备方法 |
CN103505664A (zh) * | 2012-06-28 | 2014-01-15 | 天津天狮生物发展有限公司 | 一种含有决明子的降血脂组合物及制备方法 |
CN103462129A (zh) * | 2013-08-15 | 2013-12-25 | 当涂县瑞龙果树种植专业合作社 | 一种降血脂仙人掌果粒饮料及其制作方法 |
CN103432522A (zh) * | 2013-08-26 | 2013-12-11 | 赵晶晶 | 一种治疗高血脂症的中药配方 |
CN107095981A (zh) * | 2017-05-08 | 2017-08-29 | 英山县人民医院 | 一种治疗痰浊阻滞型高血脂症的中药组合物 |
CN108813511A (zh) * | 2018-05-23 | 2018-11-16 | 安徽省六尺春翠农业科技有限公司 | 一种葛根降血脂保健品及其加工方法 |
CN109329689A (zh) * | 2018-11-12 | 2019-02-15 | 天津市农业生物技术研究中心 | 一种养生固体饮料及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101274084A (zh) * | 2007-12-18 | 2008-10-01 | 秦庆吉 | 治疗高血压和高血脂及其并发症的药物 |
CN101274042A (zh) * | 2008-05-15 | 2008-10-01 | 天科仁祥技术(北京)有限责任公司 | 治疗高脂血症的药物组合物及其制备方法 |
-
2010
- 2010-11-09 CN CN2010105362091A patent/CN102000299B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102000299A (zh) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102000299B (zh) | 一种治疗高脂血症的药物 | |
CN100518807C (zh) | 一种治疗肝硬化腹水的药物 | |
CN101284105A (zh) | 用于治疗心脑血管病的溶栓降脂丹 | |
CN103341064B (zh) | 一种治疗癃闭的中药组合物 | |
CN104013849A (zh) | 一种治疗高血压病的中药组合物及其制备方法 | |
CN102430079A (zh) | 一种治疗淋证的中药组合物 | |
CN103041360B (zh) | 一种治疗功能性腹泻和肠易激综合征的口服液 | |
CN104623598A (zh) | 一种治疗脾胃虚寒的中药组合物 | |
CN102210820A (zh) | 一种治疗白血病的中药组合物 | |
CN101961401B (zh) | 一种具有减肥降脂健脾功效的复方中药组合物 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN104083728B (zh) | 抗癌消瘤浓缩丸的加工方法 | |
CN100509025C (zh) | 一种治疗糖尿病的药物 | |
CN101987140A (zh) | 防治高脂血症中药保健茶 | |
CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 | |
CN105106895B (zh) | 一种治疗肾炎的复方中药口服液及其制备工艺 | |
CN103933538A (zh) | 用于治疗脾肾阳虚型肝硬化腹水的药物及其制备方法 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN107890521A (zh) | 一种护肝明目的中药组合物及其丸剂的制备方法 | |
CN102940820A (zh) | 一种治疗腹泻的中药组合物 | |
CN103041233A (zh) | 一种治疗小儿腹泻的药物组合物及其制备方法 | |
CN106166262A (zh) | 一种治疗慢性肾衰竭的中药组合物 | |
CN100998728A (zh) | 一种治疗阳虚型便秘的内服中药 | |
CN104623057A (zh) | 一种治疗糖尿病足的药物组合物及其应用 | |
CN103961603B (zh) | 一种降血脂通脉的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20131109 |